259 related articles for article (PubMed ID: 11129129)
1. Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials.
Yki-Järvinen H
Drugs; 2000 Nov; 60(5):975-83. PubMed ID: 11129129
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
Tandon N; Ali MK; Narayan KM
Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological strategies to reduce cardiovascular risk in type 2 diabetes mellitus: an update.
Hovens MM; Tamsma JT; Beishuizen ED; Huisman MV
Drugs; 2005; 65(4):433-45. PubMed ID: 15733008
[TBL] [Abstract][Full Text] [Related]
4. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
5. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones.
Florkowski CM
Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995
[TBL] [Abstract][Full Text] [Related]
6. Preventing macrovascular disease in patients with type 2 diabetes mellitus.
Johansen OE; Birkeland KI
Am J Cardiovasc Drugs; 2003; 3(4):283-97. PubMed ID: 14728081
[TBL] [Abstract][Full Text] [Related]
7. [Cardiovascular event in elderly patients with diabetes mellitus].
Nomura K
Nihon Rinsho; 2013 Nov; 71(11):1954-9. PubMed ID: 24397165
[TBL] [Abstract][Full Text] [Related]
8. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
Gaede P; Vedel P; Larsen N; Jensen GV; Parving HH; Pedersen O
N Engl J Med; 2003 Jan; 348(5):383-93. PubMed ID: 12556541
[TBL] [Abstract][Full Text] [Related]
9. Implications of the United Kingdom prospective diabetes study.
Baldeweg SE; Yudkin JS
Prim Care; 1999 Dec; 26(4):809-27. PubMed ID: 10523461
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up after tight control of blood pressure in type 2 diabetes.
Holman RR; Paul SK; Bethel MA; Neil HA; Matthews DR
N Engl J Med; 2008 Oct; 359(15):1565-76. PubMed ID: 18784091
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.
Krentz AJ
Diabetes Obes Metab; 2003 Nov; 5 Suppl 1():S19-27. PubMed ID: 14984018
[TBL] [Abstract][Full Text] [Related]
12. [What is the most effective approach to the reduction of cardiovascular risk in type-2 diabetes mellitus?].
Simon K; Dobó E; Nádasy T; Retih I; Rácz I
Orv Hetil; 2006 Aug; 147(31):1443-6. PubMed ID: 16981416
[TBL] [Abstract][Full Text] [Related]
13. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus.
Huang ES; Meigs JB; Singer DE
Am J Med; 2001 Dec; 111(8):633-42. PubMed ID: 11755507
[TBL] [Abstract][Full Text] [Related]
14. Optimizing the diabetic formulary: beyond aspirin and insulin.
Marso SP
J Am Coll Cardiol; 2002 Aug; 40(4):652-61. PubMed ID: 12204494
[TBL] [Abstract][Full Text] [Related]
15. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial.
Hata J; Arima H; Rothwell PM; Woodward M; Zoungas S; Anderson C; Patel A; Neal B; Glasziou P; Hamet P; Mancia G; Poulter N; Williams B; Macmahon S; Chalmers J;
Circulation; 2013 Sep; 128(12):1325-34. PubMed ID: 23926207
[TBL] [Abstract][Full Text] [Related]
16. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.
Berkelmans GFN; Gudbjörnsdottir S; Visseren FLJ; Wild SH; Franzen S; Chalmers J; Davis BR; Poulter NR; Spijkerman AM; Woodward M; Pressel SL; Gupta AK; van der Schouw YT; Svensson AM; van der Graaf Y; Read SH; Eliasson B; Dorresteijn JAN
Eur Heart J; 2019 Sep; 40(34):2899-2906. PubMed ID: 30629157
[TBL] [Abstract][Full Text] [Related]
17. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
Ferdinand KC
J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
[TBL] [Abstract][Full Text] [Related]
18. The PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events): what does it mean for primary care physicians?
Singaram V; Pratley R
Diab Vasc Dis Res; 2007 Sep; 4(3):237-40. PubMed ID: 17907116
[TBL] [Abstract][Full Text] [Related]
19. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
Dailey G
Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
[TBL] [Abstract][Full Text] [Related]
20. ["Diabetes in Germany"(DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice].
Ott P; Benke I; Stelzer J; Köhler C; Hanefeld M
Dtsch Med Wochenschr; 2009 Feb; 134(7):291-7. PubMed ID: 19197810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
